NVAX Novavax Inc.

Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018

Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018

GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, November 7, 2018.

Conference call details are as follows:

Date: November 7, 2018
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 3639227
Webcast:, “Investors”/ “Events”

Conference call and webcast replay:

Dates:Starting at 7:30 p.m. ET, November 7, 2018 until
 7:30 p.m. ET November 14, 2018
Dial-in number:(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:3639227
Webcast:, “Investors”/ “Events”, until February 7, 2019

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit and connect with us on Twitter and LinkedIn.

Contact:

Investors

Erika Trahan

Senior Manager, Investor & Public Relations



240-268-2000

Westwicke Partners

John Woolford



443-213-0506

Media

Sam Brown

Mike Beyer



312-961-2502

EN
01/11/2018

Underlying

NVAXNovavax Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novavax Inc.

Free Trial
NVAX NOVAVAX INC.

Novavax Inc: 1 director

A director at Novavax Inc sold/sold after exercising options 47,312 shares at 13.900USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

05/16/24 May 16, 2024 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences...

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion. Fireside Chat details:Date:Tuesday, March 9, 2021Time:Available on-demand starting at 7:00 a.m. Eastern Time (...

March 8, 2021 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results an...

Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights 96% vaccine efficacy against original COVID-19 in UK Phase 3 trialVaccine cross-protection demonstrated against both variants circulating in the UK and South AfricaFull enrollment (~30,000 participants) in PREVENT-19 Phase 3 trialAgreements for ~300 million doses to dateAdditional 1.1 billion doses to be supplied to the COVAX Facility (jointly with Serum Institute of India)Clinical trial of variant strain vaccines as standalone and bivalent candidates expected mid-2021Company to host conference ca...

March 1, 2021 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Va...

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in JapanTakeda doses first participant in immunogenicity and safety study to support local regulatory application GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Ta...

February 26, 2021 1 EN
 PRESS RELEASE
Free
NVAX NOVAVAX INC.

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal P...

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously po...

February 22, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch